Imipenem‑Cilastatin Dosing and Use in Intra‑Abdominal Infections
Adult Dosing (Normal Renal Function)
- For adults with creatinine clearance ≥ 90 mL/min, give 500 mg IV every 6 h or 1 g IV every 8 h. 1, 2, 3
- When the isolated pathogen is only intermediately susceptible, increase to 1 g IV every 6 h. 1, 3, 4
Infusion Recommendations (Adults)
- 500 mg doses should be infused over 20–30 minutes. 1, 2
- 1 g doses should be infused over 40–60 minutes. 1, 2
Renal‑Function‑Based Dose Adjustments (Adults)
| Creatinine Clearance (CrCl) | Recommended Dose (IV) | Frequency |
|---|---|---|
| 60–89 mL/min | 400 mg (or 500 mg if intermediate susceptibility) | Every 6 h |
| 30–59 mL/min | 300 mg | Every 6 h |
| 15–29 mL/min | 200 mg | Every 6 h |
| <15 mL/min | Use only if hemodialysis is initiated within 48 h (not routinely recommended) | — |
Dose adjustments are mandatory for CrCl < 90 mL/min. 1, 4
Pediatric Dosing (Non‑CNS Infections)
- ≥ 3 months of age: 15–25 mg/kg IV every 6 h. 4, 6
- 1–3 months (weight ≥ 1500 g): 25 mg/kg IV every 6 h. 6
- 1–4 weeks: 25 mg/kg IV every 8 h. 6
- < 1 week: 25 mg/kg IV every 12 h. 6
- Maximum total daily dose: 4 g/day. 6
Pediatric Safety Restrictions
- Imipenem‑cilastatin is not recommended for pediatric CNS infections because of seizure risk. 4, 6
- Not recommended for pediatric patients < 30 kg with renal impairment (insufficient data). 4, 6
Duration of Antimicrobial Therapy
- Limit treatment to 4–7 days unless adequate source control is difficult to achieve. 2, 3, 5, 7
- Extending therapy beyond 7 days has not shown improved clinical outcomes. 2, 3, 5
Role in Empiric Therapy for Intra‑Abdominal Infections
- Imipenem‑cilastatin is a recommended carbapenem option for high‑severity community‑acquired intra‑abdominal infections. 1, 8
- It is also recommended for health‑care‑associated infections when resistant organisms are prevalent (≥ 20 % resistant Pseudomonas, ESBL‑producing Enterobacteriaceae, or multidrug‑resistant gram‑negatives). 8
Comparative Efficacy and Guideline Position
- Despite some studies suggesting combination regimens (e.g., cefepime + metronidazole) may achieve higher cure rates, imipenem‑cilastatin remains guideline‑recommended for intra‑abdominal infections. 1, 2, 3
Safety Considerations
- Seizure risk is increased in patients with CNS disorders. 6
All facts are derived from cited sources; strength of evidence was not explicitly stated in the source material.